Neurotrope Chief Scientific Officer to Present Keynote Address at Sachs Associates’ 1st Annual Neuroscience Biopartnering & Investment Forum
February 23, 2016 08:30 ET
|
Neurotrope BioScience
NEWARK, N.J., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Neurotrope, Inc. (NTRP), a clinical-stage company developing a disruptive therapy for the treatment of severe Alzheimer’s disease (AD), today...
Neurotrope Announces Changes to Board of Directors
February 19, 2016 09:00 ET
|
Neurotrope BioScience
NEWARK, N.J., Feb. 19, 2016 (GLOBE NEWSWIRE) -- Neurotrope, Inc. (NTRP), a clinical-stage company developing a disruptive therapy for the treatment of severe Alzheimer’s disease, today announced...
Neurotrope Doses First Patients in Phase 2b Study of Bryostatin for Treatment of Severe Alzheimer’s Disease
February 11, 2016 08:30 ET
|
Neurotrope BioScience
NEWARK, N.J., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Neurotrope, Inc. (NTRP) today announced that the first patients have been dosed in the Company’s Phase 2b clinical trial of its lead candidate,...
Neurotrope CSO to Participate in Alzheimer’s Panel at 18th Annual BIO CEO & Investor Conference
February 04, 2016 11:19 ET
|
Neurotrope BioScience
NEWARK, N.J., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Neurotrope, Inc. (NTRP) today announced that its Chief Scientific Officer, Dr. Daniel Alkon, has been invited to present on a panel focused on new...
Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for Treatment of Alzheimer’s Disease
February 03, 2016 08:30 ET
|
Neurotrope BioScience
NEWARK, N.J., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Neurotrope, Inc. (OTCBB:NTRP) today announced that it has held an Investigators Meeting in conjunction with its recently initiated Phase 2b trial...
Neurotrope Initiates Phase 2b Study of Bryostatin for Treatment of Alzheimer’s Disease
January 07, 2016 08:30 ET
|
Neurotrope BioScience
NEWARK, N.J., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Neurotrope, Inc. (OTCBB:NTRP) today announced the initiation of a Phase 2b clinical trial of lead candidate Bryostatin 1 for the treatment of...